Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease.
Biochem Pharmacol
; 197: 114933, 2022 03.
Article
em En
| MEDLINE
| ID: mdl-35093393
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is becoming an increasingly serious disease worldwide. Unfortunately, no specific drug has been approved to treat NAFLD. Accumulating evidence suggests that lipotoxicity, which is induced by an excess of intracellular triacylglycerols (TAGs), is a potential mechanism underlying the ill-defined progression of NAFLD. Under physiological conditions, a balance is maintained between TAGs and free fatty acids (FFAs) in the liver. TAGs are catabolized to FFAs through neutral lipolysis and/or lipophagy, while FFAs can be anabolized to TAGs through an esterification reaction. However, in the livers of patients with NAFLD, lipophagy appears to fail. Reversing this abnormal state through several lipophagic molecules (mTORC1, AMPK, PLIN, etc.) facilitates NAFLD amelioration; therefore, restoring failed lipophagy may be a highly efficient therapeutic strategy for NAFLD. Here, we outline the lipophagy phases with the relevant important proteins and discuss the roles of lipophagy in the progression of NAFLD. Additionally, the potential candidate drugs with therapeutic value targeting these proteins are discussed to show novel strategies for future treatment of NAFLD.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Autofagia
/
Sistemas de Liberação de Medicamentos
/
Metabolismo dos Lipídeos
/
Hepatopatia Gordurosa não Alcoólica
/
Fígado
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Biochem Pharmacol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China